5297-92-7Relevant academic research and scientific papers
Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects
Hong, Cho Rong,Dickson, Benjamin D.,Jaiswal, Jagdish K.,Pruijn, Frederik B.,Hunter, Francis W.,Hay, Michael P.,Hicks, Kevin O.,Wilson, William R.
, p. 265 - 280 (2018/10/05)
Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug with proven efficacy against hypoxic cells in preclinical tumour models. TH-302 is designed to release the DNA crosslinking agent bromo-isophosphoramide mustard (Br-IPM) when reduced in h
